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Measurement of tumour volume by MRI 
to evaluate risk of pelvic nodal metastases 
in early cervical carcinoma patients
Andrzej LEBIODA, Roman MAKAREWICZ, Agnieszka ŻYROMSKA, 
Marek SZYMAŃSKI, Elżbieta SOKOLSKA
ABSTRACT
BACKGROUND: Apart from the FIGO staging system there are several other factors, including tumour 
volume and lymph node status, which considerably infl uence local tumour control and survival of 
cervical carcinoma patients.
AIM: The study aimed to determine the prognostic value of cervical tumour volume measured on the 
basis of MRI in terms of pelvic nodal metastases prediction in early cervical carcinoma patients.
METHODS: The records of 49 early stage cervical carcinoma patients treated with preoperative 
brachytherapy and radical hysterectomy were analyzed. All patients underwent diagnostic MRI, which 
was the basis for tumour volume calculations as well as the evaluation of pelvic lymph nodes status 
and parametrial invasion. In each case the postoperative pathological diagnosis was obtained. The 
correlation between the occurrence of nodal metastases and such variables as tumour histology, 
grade and tumour volume, FIGOMRI stage IIB, and patients’ age was evaluated. Logistic regression 
analysis was employed to determine correlations between tumour volume and histological pelvic 
nodal involvement.
RESULTS: A statistically signifi cant correlation between pelvic lymph node involvement and such pa-
rameters as tumour volume and parametrial invasion was proven. The probability of lymph node me-
tastasis is 20% for tumour volume of 17 cm3 and increases up to 50% for tumour volume of 40 cm3. 
An increase of tumour volume by 1 cm3 increased the risk of lymph node disease by 6.2%. 
CONCLUSIONS: The study demonstrates that tumour volume may be considered a predicting factor 
in early cervical carcinoma patients, since it strongly correlates with pelvic lymph node histological 
status.
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INTRODUCTION
The FIGO staging system is commonly con-
sidered to be a convincing predictor of cervi-
cal carcinoma treatment outcome. However, 
there are several other factors, including tu-
mour volume and lymph node status, which 
are not assessed by this system, still reported 
to be meaningful predictors as well. A proven 
indicator infl uencing the probability of local 
tumour control and survival is cervical tu-
mour size [1, 2]. In contrast, a defi nition of 
early cervical carcinoma (stage IB and IIA) 
includes a wide variety of tumour dimensions 
ranging from the smallest visible tumours 
with no pathologically involved lymph nodes 
to bulky tumours with a great probability of 
invasion to pelvic and periaortic nodes. The 
limited reliability and objectiveness of physi-
cal examination impel us to use different 
three-dimensional imaging techniques for tu-
mour size estimation [3, 4]. MRI is an espe-
cially valuable method for identifying the pri-
mary tumour as well as lymph node disease 
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and distant metastases. However, there are 
doubts whether the MRI-based estimation of 
tumour diameter or invasion depth accurate-
ly refl ects three-dimensional tumour extent. 
Since tumour volume can vary considerably 
within one FIGO stage, there is a high prob-
ability that it has great value in predicting 
lymph node involvement, a feature which de-
creases 5-year survival by 30–40% [1, 5].
AIM
The present study aimed to estimate the prog-
nostic value of tumour volume in prediction of 
pelvic nodal metastases in early-stage cervi-
cal carcinoma patients.
MATERIAL AND METHODS
Selection of patients
Between January 2004 and December 2005 a 
total of 49 cervical carcinoma patients (clini-
cal stage IB1 and IIA) were treated with pre-
operative brachytherapy and radical hyster-
ectomy at the Chair and Clinic of Oncology 
and Brachytherapy and the Chair and Clinic 
of Obstetrics and Gynaecology. From the to-
tal of 108 cervical cancer patients treated 
with LDR brachytherapy 70 patients (65%) 
were staged IB and IIA, and 38 (35%) pre-
sented more advanced disease. Sixty-four 
IB1 and IIA patients underwent preoperative 
brachytherapy and 6 patients were irradiated 
postoperatively.
Diagnostic MRI was performed in 49 out 
of 64 patients who underwent preoperative 
brachytherapy. The mean age of patients was 
49 years (range 31–75 years). The clinical stag-
ing was based on the recommendations of the 
International Federation of Gynecology and 
Obstetrics (FIGO) and comprised the follow-
ing: general clinical examination, gynaecologi-
cal examination under general anaesthesia, 
cervical biopsy, routine blood counts, blood 
chemistry profi le, chest X-ray, cystoscopy and 
ultrasonography of the abdomen and pelvis. 
The pathological diagnosis of most patients was 
squamous cell carcinoma, except in 3 cases, in 
which adenocarcinoma was proven. Character-
istics of patients are given in Table 1.
Image analysis
Before brachytherapy commencement all 
patients underwent MRI examination of the 
pelvis (1.5T scanner, Siemens, Erlangen, 
Germany), which served for the evaluation 
of primary tumour, lymph node enlargement 
and tumour volume computations. MRI out-
comes were revealed to the gynaecologist 
but the outcomes did not infl uence the deci-
sion regarding surgery, even in the presence 
of enlarged lymph nodes or infi ltration of the 
proximal parametria.
DICOM formats of T2-weighted pelvis im-
ages were sent to the treatment planning sys-
tem. The tumour area was identifi ed and de-
lineated on each MRI scan by the oncologist 
with the assistance of a radiologist, who was 
blind to clinical and pathological fi ndings.
Tumour volumes (TV) were calculated au-
tomatically using the Oncentra MasterPlan 
(Nucletron, Veenendaal, the Netherlands; 
Figure 1). Lymph nodes greater than 10 mm 
in the short axis were interpreted as positive 
ones. Proximal parametrium involvement was 
classifi ed as FIGOMRI stage IIB.
Treatment
Prior to surgery all patients received intra-
cavitary caesium treatment in two sessions 
Patients’ characteristics
Factor Value
Age [years]
Mean 49
Range 31–74
FIGOMRI stage
I 39 (80%)
II 10 (20%)
Tumor grade
I 0
II 12
III 8
unknown 29
Tumor volume [cm3]
Mean 32
Range 1.1–118
pN(-) 30 (61%)
pN(+) 19 (38%)
Table 1. Characteristics of patients (N=49)
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with a two-week interval in between. The low 
dose rate afterloading technique was used and 
a total dose of 45 Gy to point A was given. Five 
to six weeks after completion of radiotherapy 
radical hysterectomy with vaginal resection 
limited to the upper one-third was performed. 
Periaortic lymphadenectomy was not routine-
ly performed.
Statistical analysis
Pathologically confi rmed pelvic lymph node 
involvement was the endpoint of the study. 
Correlations between different variables and 
lymph node involvement were assessed using 
univariate logistic regression. Multivariate 
logistic regression analysis was employed to 
determine correlations between statistically 
signifi cant variables, identifi ed in univariate 
logistic regression, and nodal involvement. 
The second step was to eliminate irrelevant 
statistics from multivariate logistic regres-
sion variables. Odds ratio (OR) and its 95% 
confi dential interval (CI) were calculated.
Additionally, a sigmoid risk curve was 
drawn and its coeffi cient was obtained. The 
maximum likelihood method enabled the best 
adjusted risk curve to be drawn and the sta-
tistical signifi cance of the adjustment to be 
assessed. A value of p=0.05 was accepted 
as statistically signifi cant. Tumour volumes 
were computed for both distinguished patient 
groups, with and without lymph node disease, 
and compared with Student’s t-test.
RESULTS
Pelvic nodal metastases (pN+) were found in 
18 (38%) out of 48 operated patients. Addition-
ally, one patient who did not undergo surgery 
due to confi rmed skin metastasis was also 
attached to this group. Thus 30 (61%) out of 
49 patients represented negative lymph node 
status. In the whole group of patients approxi-
mately 13 lymph nodes (SD 7.2; range 3–38) 
were removed. In groups pN(+) and pN(-) ap-
proximately 11 (SD 2.5; range 3–38) and 14 
(SD 5.5; range 4–25) lymph nodes were re-
moved, respectively. In group pN(+) were ob-
served a vessel embolism of neoplasm cells in 
fi ve patients and an extracapsular infi ltration 
in three others. The mean tumour volume was 
32 cm3 (SD 30 cm3). In patients with nodal me-
tastases tumour volumes were signifi cantly 
higher compared to those in patients with no 
nodal involvement: 55.8 cm3 (SD 32.8 cm3) vs. 
18.4 cm3 (SD 26 cm3; t test, p=0.008; Figure 
2). The correlation between nodal metastasis 
Fig. 1. T2-weighted MRI scan – delineated tumour (white line) 
is visible as a low-signal mass comprising the central part of the 
uterine cervix. The calculated tumour volume is shown
Fig. 2. Tumour volume parameters categorized into two groups 
according to the status of pelvic lymph nodes, pN(+) – positive 
(metastatic) lymph nodes, pN(-) – negative lymph nodes
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occurrence (pathologically confi rmed) and 
such parameters as tumour volume, FIGOMRI 
stage IIB (unexpected fi ndings in 10 patients), 
lymph node > than 10 mm in MRI (1 pt), tu-
mour pathological type and grade as well as 
patient’s age was determined.
In the univariate logistic regression, statis-
tical signifi cance was found for 2 parameters 
only, tumour volume (p=0.00001) and FIGOMRI
stage IIB (p<0.03).
The multivariate logistic regression, in 
which the variables tumour volume and 
FIGOMRI stage IIB were used, revealed a mu-
tual association between them. This associa-
tion resulted in loss of statistical signifi cance 
of FIGOMRI stage IIB. This was the reason 
for its exclusion in further analysis. Spear-
man’s correlation coeffi cient between TV and 
FIGOMRI stage IIB was R=0.64.
Figure 3 represents the risk of pelvic lymph 
node involvement as a function of tumour vol-
ume defi ned on the basis of MRI images. The 
probability of lymph node metastasis is 20% 
for tumour volume of 17 cm3 and increases 
up to 50% for tumour volume of 40 cm3. The 
logistic regression analysis showed that each 
1 cm3 of tumour volume increases the risk of 
pelvic lymph node involvement by 6.2% (odds 
ratio 1.062; 95% CI 1.023-1.1). The model pre-
dicts an 8% risk for the “0” cm3 tumour vol-
ume (invisible tumour).
The sensitivity and specifi city of MRI in the 
assessment of pathologically affected lymph 
nodes were 5.5% (1/18) and 100% (30/30), re-
spectively.
DISCUSSION
In patients with cervical carcinoma MRI has 
been extensively evaluated and reported to be 
currently the most accurate imaging modality 
for tumour measurement and delineation [7, 8, 
9, 10]. The role of MRI cannot be overestimat-
ed when allowing for the fact that tumour size 
is a strong predictor of local control in radi-
cally treated patients, including those who are 
irradiated. According to Ito and co-workers 
tumour mass has a statistically signifi cant in-
fl uence on both tumour response rate after 2 
months and survival [11].
Mitchell reported an odds ratio of 4.1 (1.5–
11.5, 95% CI) for detection of histological 
lymph node involvement for average tumour 
size using a threshold of > 3cm versus =< 3 
cm [12]. Sahadev demonstrated an increase in 
the incidence of nodal metastasis with tumour 
size. Rate of nodal infi ltration varied from 
1.6% when no residual primary tumour was 
present, 11.5% when the primary tumour was 
< 2 cm, 33% in tumours between 2 and 4 cm, 
to 37.5% in tumours greater than 4 cm [13].
Some documented facts contradict the as-
sumption that the risk of pelvic nodal involve-
ment depends on tumour volume. Miller and 
Grisgby showed that in advanced cervical 
carcinoma both tumour volume and lymph 
node status strongly predict survival but do 
not correlate with each other [6]. The authors 
explain the phenomenon with diversifi ed bio-
logical characteristics of different tumours 
independently of their size.
Their conclusions were based on an analy-
sis of the relationship between tumour volume 
and macroscopic lymph node disease visual-
ized with PET-CT. In our study pelvic node 
involvement was in each case confi rmed by 
pathological examination. Our principal fi nd-
ing is the correlation between tumour volume 
and lymph node status. The frequency of lymph 
node metastases was signifi cantly higher in pa-
tients with larger tumour volumes compared 
with those with smaller ones. An increase of 
tumour volume by 1 cm3 increased the risk 
of nodal involvement by 6.2%. In the current 
Fig. 3. Relationship between the risk of pelvic nodal involvement 
and tumour volume, the logistic regression equation
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FIGO system nodal involvement is not taken 
into account when assessing disease stage. It is 
well known, however, that positive lymph nodes 
are the most signifi cant, apart from distant me-
tastases, prognostic factor for recurrence and 
death in cervical cancer patients.
We realize that the relatively small group 
of patients that might have infl uenced the sta-
tistical power of the analysis is a major limi-
tation of our results. However, the important 
fact is that our model allowed us to distinguish 
a group of patients whose risk of lymph node 
disease is low, for example less than 10% or 
15% (predicted for the volume of 4 cm3 and 11 
cm3, respectively). A more pronounced risk, 
for example higher than 50% (predicted in 
our model for 41 cm3) could suggest a change 
in the treatment strategy, such as excluding 
surgery. Unquestionably, further studies, with 
a higher number of patients, are required to 
confi rm the presented preliminary results. 
So far our retrospective research, restricted 
to one hospital, does not allow us to give any 
strong recommendations on treatment proto-
col changing depending on tumour volume and 
thus the risk of pelvic node metastasis, and is 
only a monograph to discuss that topic.
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